🇺🇸 LBL-007 in United States
1 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 1
Most-reported reactions
- Myelosuppression — 1 report (100%)
Other Oncology approved in United States
Frequently asked questions
Is LBL-007 approved in United States?
LBL-007 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for LBL-007 in United States?
BeiGene is the originator. The local marketing authorisation holder may differ — check the official source linked above.